Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation

Nature Biotechnology

Volumn 33, Issue 8, 2015, Pages 845-852

  Sampaziotis, Fotios ^a,e   De Brito, Miguel Cardoso ^a   Madrigal, Pedro ^a,b   Bertero, Alessandro ^a   Saeb Parsy, Kourosh ^a   Soares, Filipa A C ^a   Schrumpf, Elisabeth ^c,d   Melum, Espen ^c   Karlsen, Tom H ^c,d   Bradley, J Andrew ^a   Gelson, William T H ^e   Davies, Susan ^e   Baker, Alastair ^f   Kaser, Arthur ^a   Alexander, Graeme J ^g   Hannan, Nicholas R F ^a   Vallier, Ludovic ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOACTIVITY; BODY FLUIDS; CELL ENGINEERING; PHOSPHATASES; PHYSIOLOGICAL MODELS; STEM CELLS;

ALKALINE PHOSPHATASE ACTIVITY; BIOLOGICAL MECHANISMS; DIRECTED DIFFERENTIATIONS; FUNCTIONAL CHARACTERISTICS; HEALTHY INDIVIDUALS; HUMAN-INDUCED PLURIPOTENT STEM CELLS; PHYSIOLOGICAL RESPONSE; VASCULAR ENDOTHELIAL GROWTH FACTOR;

DIAGNOSIS;

ALKALINE PHOSPHATASE; BILE ACID; GAMMA GLUTAMYLTRANSFERASE; LUMACAFTOR; OCTREOTIDE; SECRETIN; SOMATOSTATIN; VASCULOTROPIN; VERAPAMIL;

ALAGILLE SYNDROME; ARTICLE; BILE DUCT DISEASE; CELL DIFFERENTIATION; CELLS BY BODY ANATOMY; CHOLANGIOCYTE LIKE CELL; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFECT; DRUG SCREENING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER POLYCYSTIC DISEASE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; BIOLOGICAL MODEL; CELL CULTURE; CYTOLOGY; DRUG DEVELOPMENT; DRUG EFFECTS; HEPATOBILIARY SYSTEM; INDUCED PLURIPOTENT STEM CELL; LIVER DISEASE; MEDICAL RESEARCH; METABOLISM; PHYSIOLOGY;

BILIARY TRACT; BIOMEDICAL RESEARCH; CELLS, CULTURED; DRUG DISCOVERY; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LIVER DISEASES; MODELS, BIOLOGICAL;

EID: 84938883598     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3275     Document Type: Article

References (48)

1. Lazaridis, K.N., Strazzabosco, M. & Larusso, N.F. The cholangiopathies: disorders of biliary epithelia. Gastroenterology 127, 1565-1577 (2004).
2. Murray, K.F., Carithers, R.L. Jr. & AASLD. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 41, 1407-1432 (2005).
3. Pollheimer, M.J., Trauner, M. & Fickert, P. Will we ever model PSC?-"it's hard to be a PSC model!". Clin. Res. Hepatol. Gastroenterol. 35, 792-804 (2011).
4. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676 (2006).
5. Robinton, D.A. & Daley, G.Q. The promise of induced pluripotent stem cells in research and therapy. Nature 481, 295-305 (2012).
6. Sampaziotis, F., Segeritz, C.P. & Vallier, L. Potential of human induced pluripotent stem cells in studies of liver disease. Hepatology doi:10.1002/hep.27651 (2014).
7. Zhao, D. et al. Derivation and characterization of hepatic progenitor cells from human embryonic stem cells. PLoS ONE 4, e6468 (2009).
8. Tanimizu, N., Miyajima, A. & Mostov, K.E. Liver progenitor cells develop cholangiocyte-type epithelial polarity in three-dimensional culture. Mol. Biol. Cell 18, 1472-1479 (2007).
9. Dianat, N. et al. Generation of functional cholangiocyte-like cells from human pluripotent stem cells and HepaRG cells. Hepatology 60, 700-714 (2014).
10. Si-Tayeb, K., Lemaigre, F.P. & Duncan, S.A. Organogenesis and development of the liver. Dev. Cell 18, 175-189 (2010).
11. Rashid, S.T. et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J. Clin. Invest. 120, 3127-3136 (2010).
12. Hannan, N.R., Segeritz, C.P., Touboul, T. & Vallier, L. Production of hepatocyte-like cells from human pluripotent stem cells. Nat. Protoc. 8, 430-437 (2013).
13. Xia, X., Francis, H., Glaser, S., Alpini, G. & LeSage, G. Bile acid interactions with cholangiocytes. World J. Gastroenterol. 12, 3553-3563 (2006).
14. Kanno, N., LeSage, G., Glaser, S., Alvaro, D. & Alpini, G. Functional heterogeneity of the intrahepatic biliary epithelium. Hepatology 31, 555-561 (2000).
15. Minagawa, N., Ehrlich, B.E. & Nathanson, M.H. Calcium signaling in cholangiocytes. World J. Gastroenterol. 12, 3466-3470 (2006).
16. Gigliozzi, A. et al. Molecular identification and functional characterization of Mdr1a in rat cholangiocytes. Gastroenterology 119, 1113-1122 (2000).
17. Cízková, D., Morký, J., Micuda, S., Osterreicher, J. & Martínková, J. Expression of MRP2 and MDR1 transporters and other hepatic markers in rat and human liver and in WRL 68 cell line. Physiol. Res. 54, 419-428 (2005).
18. Antoniou, A. et al. Intrahepatic bile ducts develop according to a new mode of tubulogenesis regulated by the transcription factor SOX9. Gastroenterology 136, 2325-2333 (2009).
19. Clotman, F. et al. Control of liver cell fate decision by a gradient of TGF beta signaling modulated by Onecut transcription factors. Genes Dev. 19, 1849-1854 (2005).
20. Turnpenny, P.D. & Ellard, S. Alagille syndrome: pathogenesis, diagnosis and management. Eur. J. Hum. Genet. 20, 251-257 (2012).
21. Bray, S.J. Notch signalling: a simple pathway becomes complex. Nat. Rev. Mol. Cell Biol. 7, 678-689 (2006).
22. Saravanamuthu, S.S., Gao, C.Y. & Zelenka, P.S. Notch signaling is required for lateral induction of Jagged1 during FGF-induced lens fiber differentiation. Dev. Biol. 332, 166-176 (2009).
23. Geisler, F. & Strazzabosco, M. Emerging roles of Notch signaling in liver disease. Hepatology 61, 382-392 (2015).
24. Zong, Y. et al. Notch signaling controls liver development by regulating biliary differentiation. Development 136, 1727-1739 (2009).
25. Raynaud, P. et al. A classification of ductal plate malformations based on distinct pathogenic mechanisms of biliary dysmorphogenesis. Hepatology 53, 1959-1966 (2011).
26. Chandok, N. Polycystic liver disease: a clinical review. Ann. Hepatol. 11, 819-826 (2012).
27. Temmerman, F. et al. Systematic review: the pathophysiology and management of polycystic liver disease. Aliment. Pharmacol. Ther. 34, 702-713 (2011).
28. Caroli, A. et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin. J. Am. Soc. Nephrol. 5, 783-789 (2010).
29. Marinelli, R.A. et al. Secretin induces the apical insertion of aquaporin-1 water channels in rat cholangiocytes. Am. J. Physiol. 276, G280-G286 (1999).
30. Gong, A.Y. et al. Somatostatin stimulates ductal bile absorption and inhibits ductal bile secretion in mice via SSTR2 on cholangiocytes. Am. J. Physiol. Cell Physiol. 284, C1205-C1214 (2003).
31. Caperna, T.J., Blomberg, L.A., Garrett, W.M. & Talbot, N.C. Culture of porcine hepatocytes or bile duct epithelial cells by inductive serum-free media. In Vitro Cell. Dev. Biol. Anim. 47, 218-233 (2011).
32. Masyuk, T.V., Masyuk, A.I., Torres, V.E., Harris, P.C. & Larusso, N.F. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology 132, 1104-1116 (2007).
33. Rowe, S.M., Miller, S.B. & Sorscher, E.J. Cystic Fibrosis. N. Engl. J. Med. 352, 1992-2001 (2005).
34. Davies, J.C., Alton, E.W. & Bush, A. Cystic fibrosis. Br. Med. J. 335, 1255-1259 (2007).
35. Colombo, C. Liver disease in cystic fibrosis. Curr. Opin. Pulm. Med. 13, 529-536 (2007).
36. Staufer, K., Halilbasic, E., Trauner, M. & Kazemi-Shirazi, L. Cystic fibrosis related liver disease-another black box in hepatology. Int. J. Mol. Sci. 15, 13529-13549 (2014).
37. Haack, A., Aragão, G.G. & Novaes, M.R. Pathophysiology of cystic fibrosis and drugs used in associated digestive tract diseases. World J. Gastroenterol. 19, 8552-8561 (2013).
38. Hannan, N.R., Sampaziotis, F., Segeritz, C., Hanley, N. & Vallier, L. Generation of distal airway epithelium from multipotent human foregut stem cells. Stem Cells Dev. doi:10.1089/scd.2014.0512 (2015).
39. Ward, C.L. & Kopito, R.R. Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins. J. Biol. Chem. 269, 25710-25718 (1994).
40. Shenoy, A. et al. Calcium-modulated chloride pathways contribute to chloride flux in murine cystic fibrosis-affected macrophages. Pediatr. Res. 70, 447-452 (2011).
41. Van Goor, F. et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl. Acad. Sci. USA 108, 18843-18848 (2011).
42. Clancy, J.P. et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67, 12-18 (2012).
43. Yanai, M. et al. FGF signaling segregates biliary cell-lineage from chick hepatoblasts cooperatively with BMP4 and ECM components in vitro. Dev. Dyn. 237, 1268-1283 (2008).
44. Hannan, N.R. et al. Generation of multipotent foregut stem cells from human pluripotent stem cells. Stem Cell Reports 1, 293-306 (2013).
45. Du, P. & Kibbe, W. Lin SM lumi: a pipeline for processing Illumina microarray. Bioinformatics 24, 1547-1548 (2008).
46. Smyth, G.K. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, 3 (2004).
47. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. 57, 289-300 (1995).
48. Ramsay, J.O. & Silverman, B.W. Functional Data Analysis 2nd edn. (Springer, New York, 2006).